IN-111 PENTETREOTIDE IN THE DIAGNOSTIC WORK-UP OF PATIENTS WITH BRONCHOGENIC-CARCINOMA

In a prospective study we examined 38 patients with primary bronchogen ic carcinoma to validate the use of indium-111 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the stu dy was to investigate whether (a) the disease can be reliably detected , (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT pr ovides further information on metastatic disease. After giving their i nformed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emissi on tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of prima ry tumour were correctly identified (true-positive, TP); one was false -negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung, bone and brain), while the findings were FN in five cases. An a dditional six FN findings resulted in the area of the upper abdomen du e to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, ad enocarcinoma. Metastases were TP in nine cases and FN in one. We there fore conclude: (1) IPT is a highly sensitive method for the detection of primary bronchogenic carcinoma, and in particular SCLC, (2) differe ntiation between SCLC and NSCLC cannot be achieved and (3) the method is of limited use in the search for metastatic disease. Compared with the conventional imaging modalities like X-ray, CT and bone scintigrap y, IPT provides only a small amount of additional diagnostic informati on.